SCHEMBL4675743

SCHEMBL4675743

O=C(C=C(O)c1nn[nH]n1)c1cc(S(=O)(=O)c2ccc(Cl)cc2)n[nH]1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.41
GAA P10253 1/20 0.35
ALPL P05186 3/20 0.33
CA12 O43570 1/20 0.33
KDM1A O60341 2/20 0.33
CNR1 P21554 1/20 0.33
CXCR3 P49682 2/20 0.32
KDM4E B2RXH2 1/20 0.32
PKM P14618 1/20 0.32
TBXA2R P21731 1/20 0.32
CYP2C19 P33261 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPK1 P28482 1/20 0.31
CHEK2 O96017 1/20 0.31
NAMPT P43490 1/20 0.31
PYGL P06737 1/20 0.31
CES1 P23141 1/20 0.30
NCEH1 Q6PIU2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679011 0.89 AKR1B1 (0.41) AKR1B1ALPLCA12KDM1ACXCR3
SCHEMBL4674434 0.83 AKR1B1 (0.41) AKR1B1GAAALPLCA12KDM4E
SCHEMBL4674703 0.81 AKR1B1 (0.47) AKR1B1GAAALPLCA12KDM4E
SCHEMBL4678135 0.79 AKR1B1 (0.34) AKR1B1CXCR3KDM4EPKMALDH1A1
SCHEMBL4674683 0.79 AKR1B1 (0.33) AKR1B1KDM1ACXCR3KDM4ECYP2C19
SCHEMBL4673303 0.78 ALDH1A1 (0.33) AKR1B1KDM1ACXCR3PKMTBXA2R
SCHEMBL4679497 0.78 CXCR3 (0.34) AKR1B1KDM1ACNR1CXCR3TBXA2R
SCHEMBL4671385 0.77 CXCR3 (0.33) AKR1B1KDM1ACXCR3TBXA2RCYP2C19
SCHEMBL4675056 0.77 CXCR3 (0.33) KDM1ACXCR3PKMTBXA2RCYP2C19
SCHEMBL4672177 0.77 TDP1 (0.34) AKR1B1CXCR3PKMTBXA2RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1B1 17/4885GAA 1884/4885ALPL 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.